116 related articles for article (PubMed ID: 30655841)
1. Effect of interventional embolotherapy on FHIT and p16 expression in hepatocellular carcinoma patients.
Xu W; Qi X; Wang X; Sun J
Oncol Lett; 2019 Jan; 17(1):871-876. PubMed ID: 30655841
[TBL] [Abstract][Full Text] [Related]
2. Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.
Fu Y; Shan X; Song W; Xu K; Jiao C; Zhang Q
J BUON; 2019; 24(1):40-47. PubMed ID: 30941950
[TBL] [Abstract][Full Text] [Related]
3. Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
Nan KJ; Ruan ZP; Jing Z; Qin HX; Wang HY; Guo H; Xu R
World J Gastroenterol; 2005 Jan; 11(2):228-31. PubMed ID: 15633221
[TBL] [Abstract][Full Text] [Related]
4. Expression and Prognostic Role of FHIT, Fibronectin, and PTEN in Hepatocellular Carcinoma.
Zhang MJ; Yan Q; Zhang GL; Wie YH; Yuan WB; Xu W; Huang LF
Clin Lab; 2016 Jul; 62(7):1255-1264. PubMed ID: 28164627
[TBL] [Abstract][Full Text] [Related]
5. [Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance].
Yao CC; Lin CY; Hu MB
Ai Zheng; 2004 Mar; 23(3):310-6. PubMed ID: 15025965
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
7. [Alterations of FHIT gene and p16 gene in lung cancer and metastatic hilar lymph nodes].
Wang X; Sun Y; Li W
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):108-11. PubMed ID: 11776848
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
9. [Reduction of FHIT gene expression in primary lung cancer].
Wang Y; Zhou Q; Zhang S; Cheng N; Liu L; Li L; Wu Z; Che G; Qin J
Zhongguo Fei Ai Za Zhi; 2002 Feb; 5(1):6-9. PubMed ID: 21315018
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
[TBL] [Abstract][Full Text] [Related]
11. Loss of fragile histidine triad protein in human hepatocellular carcinoma.
Zhao P; Song X; Nin YY; Lu YL; Li XH
World J Gastroenterol; 2003 Jun; 9(6):1216-9. PubMed ID: 12800227
[TBL] [Abstract][Full Text] [Related]
12. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
13. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
14. [The biological significance of FHIT protein expression in lung cancer and precancerous tissues detected by tissue microarray].
Yuan L; Wang X; Zheng H
Zhongguo Fei Ai Za Zhi; 2007 Jun; 10(3):192-6. PubMed ID: 21118644
[TBL] [Abstract][Full Text] [Related]
15. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
16. HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells.
Yu GR; Qin WW; Li JP; Hua W; Meng YL; Chen R; Yan B; Wang L; Zhang X; Jia LT; Zhao J; Zhang R; Yang AG
Biosci Rep; 2012 Jun; 32(3):271-9. PubMed ID: 21679157
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological analysis of loss of fragile histidine triad expression in lung cancer].
Zhao P; Lv Y; Zhong M; Chen L
Zhongguo Fei Ai Za Zhi; 2002 Oct; 5(5):345-8. PubMed ID: 21329602
[TBL] [Abstract][Full Text] [Related]
18. [Expression of nuclear factor-kappa-B/P65 and fragile histidine triad in colorectal carcinoma and clinical significance thereof].
Lü Y; Liu L; Zhao P
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(9):610-4. PubMed ID: 18646716
[TBL] [Abstract][Full Text] [Related]
19. Decreased fragile histidine triad gene messenger RNA expression in lung cancer.
Sasaki H; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Clin Lung Cancer; 2006 May; 7(6):412-6. PubMed ID: 16800968
[TBL] [Abstract][Full Text] [Related]
20. Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.
Wang P; Guo L; Li K; Ning S; Shi W; Liu Z; Chen Y
Cancer Biomark; 2018 Feb; 21(3):681-687. PubMed ID: 29278882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
